Prostate cancer remains significant public health concern amid growing controversies regarding prostate specific antigen (PSA) based screening.
The utility of PSA has been brought into question, and alternative measures are investigated to remedy the overdetection of indolent disease and safeguard patients from the potential harms resulting from an elevated PSA. Multiparametric MRI of the prostate has shown promise in identifying patients at risk for clinically significant disease but its role within the current diagnostic and treatment paradigm remains in question. The current review focuses on recent applications of MRI in this pathway.
Written by:
George AK, Pinto PA, Rais-Bahrami S. Are you the author?
National Cancer Institute, Urologic Oncology Branch, National Institutes of Health, 10 Center Drive, 2950-W, Building 10, CRC Room 2W-5940, Bethesda, MD 20892-1210, USA.
Reference: Biomed Res Int. 2014;2014:465816.
doi: 10.1155/2014/465816
PubMed Abstract
PMID: 25250323